Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [726]

Choosing Wisely: Managing resectable colorectal liver metastases

Dr Christopher Jackson - University of Otago, Otago, New Zeland

Choosing Wisely: Managing resectable colorectal liver metastases ( Dr Christopher Jackson - University of Otago, Otago, New Zeland )

Optimal management of gastric cancers

Dr Prasanth Penumadu - Institution of Cancer Care & Advanced Research...

Optimal management of gastric cancers ( Dr Prasanth Penumadu - Institution of Cancer Care & Advanced Research , Tirupati, India. )

Choosing Wisely: ctDNA/ Precision Oncology in colorectal cancers

Dr Aparna Parikh - Massachusetts General Hospital, Boston, EE.UU

Choosing Wisely: ctDNA/ Precision Oncology in colorectal cancers ( Dr Aparna Parikh - Massachusetts General Hospital, Boston, EE.UU )

Temab-A plus bevacizumab shows promising response rates in advanced colorectal...

Dr Michael Cecchini - Yale School of Medicine, New Haven, USA

Temab-A plus bevacizumab shows promising response rates in advanced colorectal cancer ( Dr Michael Cecchini - Yale School of Medicine, New Haven, USA )

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable...

Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia

ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable outcomes in stage III colon cancer ( Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia )

Zanzalintinib plus atezolizumab improves survival in refractory mCRC

Dr Anwaar Saeed - University of Pittsburgh, Pittsburgh, USA

$Zanzalintinib plus atezolizumab improves survival in refractory mCRC ( Dr Anwaar Saeed - University of Pittsburgh, Pittsburgh, USA )$

Trastuzumab deruxtecan demonstrates advance in treatment for HER2-positive...

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA

Trastuzumab deruxtecan demonstrates advance in treatment for HER2-positive gastric cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2...

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )

Durvalumab combined with FLOT improves survival in resectable gastric and GEJ...

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA

Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )

MCED blood test demonstrates high specificity, strong predictive value, and...

Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection ( Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA )

Circulating tumour DNA a useful marker in CRC treatment efficacy, but only...

Dr Emerik Österlund - MD Anderson Cancer Center, Houston, USA

Circulating tumour DNA a useful marker in CRC treatment efficacy, but only alongside others ( Dr Emerik Österlund - MD Anderson Cancer Center, Houston, USA )

More from ecancer